- Home
- ELEV vs IGC Comparison
ELEV vs IGC Comparison
Compare ELEV & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- IGC
- Stock Information
- Founded
- ELEV 2019
- IGC 2005
- Country
- ELEV United States
- IGC United States
- Employees
- ELEV N/A
- IGC N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- IGC Health Care
- Exchange
- ELEV Nasdaq
- IGC Nasdaq
- Market Cap
- ELEV 18.1M
- IGC 20.2M
- IPO Year
- ELEV 2021
- IGC N/A
- Fundamental
- Price
- ELEV $0.32
- IGC $0.31
- Analyst Decision
- ELEV Buy
- IGC Strong Buy
- Analyst Count
- ELEV 6
- IGC 2
- Target Price
- ELEV $2.94
- IGC $3.88
- AVG Volume (30 Days)
- ELEV 753.5K
- IGC 214.1K
- Earning Date
- ELEV 08-05-2025
- IGC 06-23-2025
- Dividend Yield
- ELEV N/A
- IGC N/A
- EPS Growth
- ELEV N/A
- IGC N/A
- EPS
- ELEV N/A
- IGC N/A
- Revenue
- ELEV N/A
- IGC $1,236,000.00
- Revenue This Year
- ELEV N/A
- IGC N/A
- Revenue Next Year
- ELEV N/A
- IGC $16.45
- P/E Ratio
- ELEV N/A
- IGC N/A
- Revenue Growth
- ELEV N/A
- IGC 1.65
- 52 Week Low
- ELEV $0.22
- IGC $0.25
- 52 Week High
- ELEV $3.77
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- ELEV 49.38
- IGC 48.79
- Support Level
- ELEV $0.29
- IGC $0.30
- Resistance Level
- ELEV $0.32
- IGC $0.33
- Average True Range (ATR)
- ELEV 0.02
- IGC 0.02
- MACD
- ELEV 0.00
- IGC -0.00
- Stochastic Oscillator
- ELEV 59.01
- IGC 13.20
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.